Navigation Links
ChanTest Announces a Complimentary Webinar on the Use of the xCELLigence System
Date:3/19/2013

Cleveland, OH (PRWEB) March 19, 2013

Cardiovascular (CV) toxicity is a leading contributor to drug withdrawal and late-stage attrition in the drug discovery process. There is an urgent need for novel in vitro assays that enable earlier and broader testing for CV activity.

ChanTest has developed a new assay using ACEA Bioscience’s xCELLigence system to measure contractility and cardiotoxicity. On Wednesday, March 20th at 1:00 p.m. EST, ChanTest will host “Get with the Beat! A New In Vitro Assay for Cardiotox and Contractility in Human Cells”, a complimentary webinar to explain the importance and advantages of this new assay.

Click here to register

Andrew Bruening-Wright, PhD, Principal Scientist at ChanTest, will provide a comprehensive overview on the evaluation of contractile activity of stem cell-derived human cardiomyocytes using impedance analysis and Dr. Dinah Misner, from Genentech, a board-certified toxicologist, will discuss her group's experience with this new xCELLigence Cardio assay.

Wednesday, March 20, 2013
Get with the Beat! A New In Vitro Assay for Cardiotox and Contractility in Human Cells
1:00 p.m. EST
Register here

FURTHER INFORMATION

ChanTest
14656 New Parkway
Cleveland, Ohio 44128
1-877-828-1777 Toll Free
1-216-332-1665 Tel
1-216-332-1706 Fax
info(at)chantest(dot)com

Contact for Media Inquiries:

Chris Mathes, Ph.D., M.B.A.
Chief Commercial Officer
cmathes(at)chantest(dot)com
http://www.chantest.com

About ChanTest® – The Ion Channel Expert

ChanTest’s mission is to serve the drug discovery and
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... TORONTO , Aug. 27, 2015 /PRNewswire/ - ... Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company ... in a Phase I study of BHV-0223, a ... application (IND) regarding BHV-0223 and recently obtained clearance ... to proceed with human testing. Portage holds 54% ...
(Date:8/27/2015)...  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading ... today announced that executives from the company will present ... , Pedro Lichtinger , Chief ... Annual Global Investment Conference on Wednesday, September 10, 2015 ... in New York City . ...
(Date:8/27/2015)... 27, 2015 HUYA Bioscience International (HUYA) today announced ... Japan Society of HTLV-1, held this week at the ... of the Society is to promote research on HTLV-1 ... medical technology and research related to these fields to ... "HUYA is proud to support this prestigious conference," said ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Inc. Magazine ... States, ranking iLab Solutions as number 1,361 in growth for the three years through ... the top 0.1% fastest-growing privately held organizations in the country. , “We are ...
Breaking Biology Technology:Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
... SEATTLE, Nov. 20 Scientists have announced,that they ... opening the possibility of patient-specific medical treatments and,research ... Wesley J. Smith, the Discovery Institute,s Senior Fellow ... Brave New World, hailed the,breakthrough as demonstrating that ...
... - ARIUS Research Inc., (TSX:,ARI), a biotechnology ... of,antibody therapeutics, today announced that Daniel S. ... at the 14th Annual BioNorth,Biotechnology and Life ... non-traditional approach to drug discovery using its ...
... 20 - Third quarter Consolidated Net Income ... Third Quarter 2006 Results Adversely Affected by,Northern Hostilities ... Issue of,Debentures Primarily for the Financing of the Strategic ... and Poor,s Affiliation Oil Refineries Ltd. (TASE: ORL) ...
Cached Biology Technology:ARIUS to present at BioNorth Biotechnology and Life Sciences Conference 2Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 2Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 3Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 4Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 5Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 6Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 7Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 8Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 9Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 10Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 11
(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
(Date:8/10/2015)... August 10, 2015 The latest 364 ... comprehensive analysis of the global border security market . ... of $16.4bn in 2015. Now: Border security is ... example of the business critical issue you need to know ... visiongain ,s objective analysis of how this will impact your ...
(Date:8/6/2015)... Aug. 6, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced collaboration with Microsoft on ... 10. Microsoft leveraged Synaptics, deep expertise in human ... Through stringent testing, Synaptics, advanced ... with Microsoft,s Precision TouchPad (PTP) specification empowering OEMs ...
Breaking Biology News(10 mins):Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... Humans spend greater than 90 percent of their time ... scientists estimate, make up half of the world,s biomasssome ... most often meet them within enclosed spaces. So, that,s ... new report issued by the National Institute of Standards ...
... new method for rapidly solving the three-dimensional structures of ... proteins, may speed drug discovery by providing scientists with ... published May 20 in Nature Methods . ... for Biological Studies, provides a shortcut for determining the ...
... of the small adrenal tumors that cause big problems with ... to retain too much sodium, researchers report. The study ... a mutation of the gene KCNJ5 is twice as likely ... as it points to potential new treatments for some patients ...
Cached Biology News:Report details efforts to improve, advance indoor microbial sampling 2Speeding up drug discovery with rapid 3-D mapping of proteins 2Speeding up drug discovery with rapid 3-D mapping of proteins 3Common genetic mutation increases sodium retention, blood pressure 2Common genetic mutation increases sodium retention, blood pressure 3
... DNase I Amplification ... double-stranded DNA to oligodeoxyribonucleotides. ... >10000 units/mg. DNAse I ... purified and tested for ...
... for the determination of digitonin and digoxin. Physical ... Na 4 and 0.06% NaCl Preparation Note: ... Biochem. Biophys. Res. Commun., 19, 755 (1965). ... of inorganic phosphorus from ATP per min at ...
... ds Qualified is a special preparation of bovine ... double stranded cleavage of DNA molecules. In the ... enzyme makes double strand breaks at random sites ... fragments can be controlled by the enzyme concentration ...
... type 14 3C protease from human rhinovirus ... the Novagen brand line of restriction grade ... purified recombinant 6XHis-fusion protein, which recognizes the ... LeuGluValLeuPheGln/GlyPro. The small, 22 KDa size of ...
Biology Products: